Please login to the form below

Not currently logged in
Email:
Password:

ADA meeting

This page shows the latest ADA meeting news and features for those working in and with pharma, biotech and healthcare.

J&J says real-world data finds no amputation risk for Invokana

J&J says real-world data finds no amputation risk for Invokana

Now, J&J has data from a patient registry involving more than 700, 000 type 2 diabetics treated with Invokana (canagliflozin) – reported at the American Diabetes Association (ADA) meeting in Orlando,

Latest news

  • Novo says real-world data backs its insulin switching Novo says real-world data backs its insulin switching

    The Danish drugmaker reported findings from its EU-TREAT patient registry study at the American Diabetes Association (ADA) meeting in San Diego on Saturday. ... Top-line data from that trial was reported late last month and will be presented as a keynote

  • IBM plans Watson-powered 'diabetes advisor' IBM plans Watson-powered 'diabetes advisor'

    The collaboration will marry IBM's Watson supercomputer with the vast repository of clinical and research data held by the ADA. ... Announcing the tie-up at the ADA's annual scientific meeting earlier this month, IBM and the ADA also outlined their plans

  • Rivals look to put pressure on Sanofi's Lantus Rivals look to put pressure on Sanofi's Lantus

    The American Diabetes Association's (ADA) Scientific Sessions meeting in Boston this weekend saw several of Sanofi's rivals claim clinical benefits over its blockbuster Lantus (insulin glargine). ... of patients reaching the ADA's target of HbA1c of less

  • Relief as study finds no cardiovascular risk with Januvia Relief as study finds no cardiovascular risk with Januvia

    The data will be scrutinised further when presented at the American Diabetes Association (ADA) meeting in Boston in June, but analysts suggested the results could help Januvia consolidate its position as

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    With that in mind, attention is fixed on the forthcoming results from the TECOS trial of Januvia, which are due to be presented at the American Diabetes Association (ADA) meeting in

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics